Th22 cells are a novel subset of CD4 + T cells that primarily mediate biological effects through IL-22, with both Th22 cells and IL-22 being closely associated with multiple autoimmune and chronic inflammatory diseases. In this study, we investigated whether and how Th22 cells affect atherosclerosis. ApoE −/− mice and agematched C57BL/6J mice were fed a Western diet for 0, 4, 8 or 12 weeks. The results of dynamic analyses showed that Th22 cells, which secrete the majority of IL-22 among the known CD4 + cells, play a major role in atherosclerosis. ApoE −/− mice fed a Western diet for 12 weeks and administered recombinant mouse IL-22 (rIL-22) developed substantially larger plaques in both the aorta and aortic root and higher levels of CD3 + T cells, CD68 + macrophages, collagen, IL-6, Th17 cells, dendritic cells (DCs) and pSTAT3 but lower smooth muscle cell (SMC) α-actin expression than the control mice. Treatment with a neutralizing anti-IL-22 monoclonal antibody (IL-22 mAb) reversed the above effects. Bone marrow-derived DCs exhibited increased differentiation into mature DCs following rIL-22 and ox-LDL stimulation. IL-17 and pSTAT3 were up-regulated after stimulation with IL-22 and ox-LDL in cells cocultured with CD4 + T cells and mature DC supernatant, but this up-regulation was significantly inhibited by IL-6mAb or the cell-permeable STAT3 inhibitor S31-201. Thus, Th22 cell-derived IL-22 aggravates atherosclerosis development through a mechanism that is associated with IL-6/STAT3 activation, DC-induced Th17 cell proliferation and IL-22-stimulated SMC dedifferentiation into a synthetic phenotype. K E Y W O R D S atherosclerosis, dendritic cells, IL-22, inflammation, smooth muscle cells, Th22 cells | 3065 SHI et al. S U PP O RTI N G I N FO R M ATI O N Additional supporting information may be found online in the Supporting Information section. How to cite this article: Shi L, Ji Q, Liu L, et al. IL-22 produced by Th22 cells aggravates atherosclerosis development in ApoE −/− mice by enhancing DC-induced Th17 cell proliferation.
| INTRODUC TI ON
Atherosclerosis (AS) is a highly complex and multifactorial disease, with current data showing that atherosclerosis is the leading cause of death among all human diseases. A growing body of evidence suggests that atherosclerosis is a chronic inflammatory disease that is closely related to innate and acquired immunity. 1, 2 During each stage of the disease, progressive atherosclerotic lesions display T-lymphocyte infiltration.
These T cells interact with local macrophages and vascular smooth muscle cells (SMCs) and affect the expression of inflammatory factors.
Inflammatory factors such as MCP-1, tumour necrosis factor-α (TNF-α) and interleukin (IL)-6, which are expressed by macrophages and T lymphocytes, facilitate SMC migration from the tunica media to the intimal or subendothelial space, resulting in the formation of a fibrous cap. [3] [4] [5] Studies have indicated that the lymphocytes present in a plaque are primarily CD4 + T cells, 6, 7 which can be roughly divided into Th1, Th2, Th17 and regulatory T (Treg) cell lineages. The Th1 cell-mediated immune response has been shown to promote the development of AS. 8, 9 Th17 cells, which are a powerful inflammatory factor, may play important roles in accelerating AS in specific environments, [10] [11] [12] [13] whereas Treg cells are atheroprotective. 14, 15 The overall role of the Th2 immune response during AS remains unclear. [16] [17] [18] Dendritic cells (DCs) are the most potent antigen-presenting cells (APCs) and express costimulatory molecules, such as CD80 and CD86. DCs possess a strong capacity to activate and promote T-cell differentiation.
These cells were demonstrated to drive CD4 + T-cell differentiation along both the Th1 and Th17 pathways, 19, 20 which partially occurs through STAT3 phosphorylation. 21, 22 The Th22 subset is a novel CD4 + T-cell subset that was discovered in humans in 2009 and is distinct from the Th1, Th2 and Th17 subsets. 13, 23, 24 In 2012, Basu et al demonstrated that Th22 cells (CD4 + IL-22 + ) are also present in mice and are the most important source of in mice. 25 Basu demonstrated that in the early stages of inflammation, IL-22 is primarily secreted by lymphatic tissue-induced cells. In the middle and late stages of inflammation, IL-22 is pre-dominantly released by Th22 cells. These results indicate that Th22 cells and IL-22 likely play an important role in chronic inflammatory diseases. The biological effects of Th22 cells occur through IL-22, which, though previously considered a Th17 cytokine, belongs to the IL-10 family and has effects that are primarily mediated through IL-22-IL-22R1 interaction. 26, 27 IL-22 binding to IL-22R1 pre-dominantly activates the STAT3 pathway. 28 In recent years, the relationship between Th22 cells and clinical disease has attracted increased attention. IL-22 protects against multiple infections of the lungs and intestine as well as liver injury, but it also has pathogenic roles in rheumatoid arthritis and psoriasis. [29] [30] [31] [32] [33] However, few studies have investigated the roles of Th22 cells and IL-22 in AS. Our previous study revealed significant increases in the peripheral Th22 cell numbers and IL-22 levels of patients with acute coronary syndrome (ACS) compared to patients with stable angina pectoris (SAP) and control patients, suggesting that the circulating Th22-type response may have a potential role in the onset of ACS symptoms. 23 In this context, we focused on elucidating whether and how Th22 cells and IL-22 act on AS.
| MATERIAL S AND ME THODS

| Animal models and interventions
Eight-week-old homozygous ApoE −/− male mice (in a C57BL/6J background) and age-matched C57BL/6J mice with bodyweights ranging from 20 to 25 g were obtained from The Jackson Laboratory housed under specific pathogen-free conditions and fed a Western-type diet (Clinton/Cybulsky Rodent Diet D12108 with 1.25% cholesterol;
Research Diets). Animal studies were performed in accordance with the National Institutes of Health Animal Care and Use guidelines, and all breeding and experiment protocols were undertaken after review and approval by the Animal Ethics and Experimental Committee of the People's Hospital of Guangxi Zhuang Autonomous Region.
Half of the ApoE −/− mice and all of the C57BL/6J mice were weighed, killed and analysed at weeks 0, 4, 8 and 12 (eight mice at each time-point, Figure S1 ). Half of the ApoE −/− mice were randomized into four groups (eight mice in each group) and intraperitoneally injected with 2 μg of recombinant IL-22 (rIL-22), 1× PBS, 20 µg of an anti-IL-22 monoclonal antibody (IL-22 mAb) or an isotype mAb (all from R&D Systems) thrice a week for 12 weeks ( Figure S1 ).
| Tissue preparation and atherosclerosis lesion evaluation
At 0, 4, 8 and 12 weeks, the mice were killed, and blood was collected retro-orbitally to assess the IL-22, IL-6, MCP-1 and TNF-α concentrations by enzyme-linked immunosorbent assays (ELISAs). The spleen, aorta and heart of each mouse were rapidly removed after perfusion with PBS. The spleens were mechanically dissociated to isolate lymphocytes for analysis of Th1, Th17 and Th22 cell frequencies by flow cytometry. The hearts and aortas were snap-frozen at −80°C for further analysis. Atherosclerotic lesions were measured by lipid staining. Hearts with an attached aortic root were snap-frozen in OCT compound, and the aortic sinus cross-sections (10 μm per section) were excised, fixed in 4% formalin and stained with oil red O. For further analysis, five sections from each mouse were obtained from five different locations (each separated by 100 μm), and the lipid deposits in the aorta were fixed and stained as described above. Before euthanasia, all mice were anesthetized with 3% chloral hydrate at 10 μL/g bodyweight. All images were captured by a single observer blinded to the experimental protocol and analysed with computer image analysis software (Image-Pro Plus 6.0).
| Cell preparation
Mice were killed at 0, 4, 8 and 12 weeks, and lymphocytes from the spleens were isolated. Immediately after being removed from the mice, the fresh spleens were gently crushed with a clear glass pestle in cold PBS, and the splenocytes were passed through a 100 mesh stainless steel screen to prepare single-cell suspensions. The cells were extracted with an equal volume of Ficoll-Hypaque and washed twice in PBS to isolate the splenic lymphocytes.
| Flow cytometry
| Analysis of IL-22-related T cells
Cells were resuspended in PBS at a density of 10 5 -10 6 cells/mL and incubated with a fluorescein isothiocyanate (FITC)-conjugated antimouse CD4 antibody at 4°C for 30 minutes for cell surface staining. After surface staining, the cells were washed twice and resuspended in RPMI-1640 medium (Gibco) supplemented with 10% heat-inactivated foetal calf serum (FCS; Gibco, BRL), also referred to as complete medium, and then transferred to 24well plates. The lymphocytes were stimulated with 2 μL of Cell Stimulation Cocktail (plus protein transport inhibitors, eBioscience). The cells were incubated at 37°C under a 5% CO 2 atmosphere. After 4 hours of culturing, the contents of the wells were transferred to sterile 5-mL tubes, where the cells were washed, fixed and permeabilized. Next, the cells were stained with allophy- 
| Analyses of mature DCs
Cells were stained with antibodies against CD11c, CD86 and MHC-II to study DC surface markers according to the manufacturer's protocols. The DC surface marker levels were measured by flow cytometry using the following antibodies: a FITC-labelled anti-CD11c antibody, a Brilliant Violet 421 (BV421)-labelled anti-CD86 antibody and a PE-labelled anti-MHC-II antibody (all of the antibodies were purchased from BioLegend Company).
| ELISA
The serum concentrations of IL-22, IL-6, MCP-1 and TNF-α were measured by ELISAs according to the manufacturer's instructions (ELISA kits for IL-6, MCP-1 and TNF-α, Neobioscience Technology;
ELISA kits for IL-22, BD Biosciences). The intra-and interassay coefficients of variation for all ELISAs were <5% and <10%, respectively.
All assays were performed in triplicate.
| Immunohistochemistry and Masson trichrome staining
Hearts with an attached aortic root were snap-frozen in OCT compound and then cut into 4-μm-thickaortic sinus cross-sections.
Four cross-sections were analysed from each mouse to quantitate the levels of IL-22, IL-22R1, macrophages, T cells, vascular SMCs and collagenin in the lesions. For immunohistochemical analyses, the sections were fixed with formalin and pre-treated with formic acid, followed by endogenous peroxidase blocking with 2% normal goat serum and incubation with primary antibodies, including a rabbit antimouse IL-22 antibody (1:500 dilution), a rabbit antimouse IL-22R1 antibody (1:25 dilution), a rabbit antimouse CD3 antibody (1:500 dilution), a rabbit antimouse CD68 antibody (e) ox-LDL (50 μg/mL); (f) ox-LDL+rIL-22 (50 μg/mL and 100 ng/ mL, respectively); (g) ox-LDL+rIL-22+IL-6mAb (50 μg/mL, 100 ng/ mL and 10 ng/mL, respectively); and (h). ox-LDL+rIL-22+S31-201 (50 μg/mL, 100 ng/mL and 10 μmol/L, respectively). Each group had 5 wells with 2 × 10 5 cells/well. The cells were cultured at 37°C under an atmosphere with 5% CO 2 for 72 h in RPMI-1640 medium (Gibco) under Th17-polarizing conditions (TGF-β, 1 ng/mL; IL-23, 50 ng/mL; anti-IFN-γ, 10 µg/mL; and anti-IL-4, 10 µg/mL; all from eBioscience, San Diego, CA) without IL-6. After 3 days of culturing, the cells were collected for RT-PCR and Western blot.
| Cell culture and intervention
| Real-time quantitative reverse transcriptionpolymerase chain reaction (RT-PCR)
Total RNA was extracted from the aortas and cells with TRIzol between the Ct value of the target gene and that of β-actin. The results are presented as the relative fold change compared with the 0-week C57BL/6J mice (assigned a value of 1) using the standard 2 −ΔΔCt method. The primer sequences for the IL-22, IL-22R1, MHC-II, CD80, CD86, IL-17 and β-actin genes are shown in Table 1 .
| Western blot analysis
Total protein was extracted from the aortas and cells and then detected with a BCA Protein Assay kit (Thermo Fisher Scientific).
Protein samples (20 μg) were separated by electrophoresis on 8% Laemmli sodium dodecyl sulphate polyacrylamide gels. Equal amounts of protein per lane were electrophoretically transferred onto Immobilon-FL PVDF membranes (Millipore). Then, the membranes were blocked with 5% non-fat milk and incubated with anti-STAT3 (1:1000; Cell Signaling Technology), anti-phosphorylated STAT3 (1:2000; Cell Signaling Technology) and anti-GAPDH antibodies at 4°C overnight followed by incubation with a goat antimouse IgG HRP-conjugated secondary antibody (1:5000, Abcam) at room temperature for 1 hour. The blots were visualized using a 2-colour infrared imaging system (Odyssey; LI-COR Biosciences).
| Statistical analysis
All data are presented as the means ± SD. Multiple-group comparisons were performed by ANOVA. Differences between two groups were compared by Student's t test, and P < .05 was considered significant. 
| RE SULTS
| Basic physiological parameters
| Th22 cells are the major source of IL-22 during atherosclerosis
To elucidate the role of Th22 cells in the development of AS, we Figure 2H ). The levels of IL-22-producing Th17 cells were higher in the ApoE −/− mice than in the control mice at all time-points, but no significant differences were observed between these groups of mice ( Figure 2F ). In addition, no significant differences were observed among the frequencies at 4, 8, 12 and 0 weeks in the ApoE −/− mice ( Figure 2F ). These results further demonstrated that among the known CD4 + cells, Th22 cells, which secrete most of the IL-22, play a major role in AS.
| IL-22 and IL-22R1 are expressed in mouse atherosclerotic plaques, and their expression levels are increased in ApoE −/− mice
As noted previously, IL-22R is expressed in various non-immune tissues, such as the skin, lungs and kidneys, and in cardiomyocytes.
Through immunohistochemical analyses, we showed that IL-22R1 is also expressed in mouse atherosclerotic plaques, and the expression levels of this molecule were similar among groups with varying degrees of atherosclerotic lesions ( Figure 3A ,B). To further explore the dynamic changes in IL-22 and IL-22R1 levels in AS, we dynamically assessed the aorta by real-time PCR analyses. We observed that the mRNA levels of IL-22 and IL-22R1 were significantly higher in the ApoE −/− mice than in the age-matched C57BL/6J mice at all timepoints ( Figure 3C,D) . IL-22R1 mRNA expression showed no significant differences at 0, 4, 8 and 12 weeks ( Figure 3D ). IL-22 mRNA expression peaked at 4 weeks and remained relatively high at 12 weeks ( Figure 3C ), and ELISAs of the serum IL-22 concentration exhibited a similar trend ( Figure 3E ).
| IL-22 aggravates atherosclerosis development
To further evaluate the role of IL-22 in the development of AS, we treated ApoE −/− mice with rIL-22 for 12 weeks. First, the plaque sizes in the aortic root and the whole aorta were analysed. We observed that the plaque area was significantly increased in the mice treated with rIL-22 compared with those treated with PBS ( Figure 4A) . Additionally, the aortic plaque burden was substantially greater in the mice treated with rIL-22 than in those treated Figure 5A ). In addition, the aortic plaque burden was notably lower in the IL-22 mAbtreated ApoE −/− mice than in the isotype mAb-treated ApoE −/− mice ( Figure 5B ). The areas occupied by CD3 + T cells and CD68 + macrophages in the plaques were also significantly decreased in the IL-22 mAb-treated mice compared with the isotype control-treated mice ( Figure 5C,D) , and the SMC numbers were substantially increased ( Figure 5E ). These findings indicated that the neutralization of IL-22 decreases the development of AS and that IL-22 exacerbates this process. 
| IL-22 promotes the phenotypic dedifferentiation of SMCs
Given the observed trend of the variation in SMC α-actin, we sub- 
| IL-22 increases DC and Th17 cell numbers by activating IL-6/STAT3
To investigate the inflammatory mechanisms by which circulating IL-22 may promote aggravated AS, we further evaluated proatherogenic cells in mouse spleens via flow cytometry and the concentration of proatherogenic inflammatory factors in the serum via ELISAs.
We observed significant increases in the levels of IL-6 and Th17 cells in the rIL-22-treated ApoE −/− mice and an strong decrease in IL-22 mAb-treated ApoE −/− mice compared with the corresponding control mice ( Figure 6A,B) . However, these interventions had no impact on other proinflammatory factors, such as TNF-α, IL-1β
and MCP-1 ( Table 2) . We observed increased Th1 cell numbers in the rIL-22-treated ApoE −/− mice and decreased numbers in the IL-22 mAb-treated ApoE −/− mice compared with the corresponding control mice. Nonetheless, no significant differences were observed among the groups (Figure 6C ). with those treated with an isotype control ( Figure 6E) . These results indicate that the mechanism by which IL-22 promotes AS is associated with activated IL-6/STAT3 and DC-mediated induction of Th17 cell proliferation.
| IL-22 induces DC maturation and Th17 cell proliferation through the IL-6/STAT3 pathway in vitro
Because we observed increased numbers of mature DCs and Th17 cells, as well as increased levels of IL-6 and pSTAT3 in rIL-22-treated ApoE −/− mice fed a western diet, we conducted cell-based experiments to further elucidate the underlying mechanisms, especially the downstream signalling pathways involved. First, we isolated bone marrow-derived DCs from ApoE −/− mice and pre-treated/untreated them with rIL-22 (100 ng/mL), followed by ox-LDL stimulation ( Figure S1 ). We observed that IL-22 up-regulated the expression of CD80 ( Figure 6F ) and CD86 ( Figure 6G 
| D ISCUSS I ON
In our study, ApoE −/− and age-matched C57BL/6J mice were killed and then analysed at weeks 0, 4, 8 and 12. We observed that IL-22R1 is expressed in aortic tissue and that Th22 cells are the major producers of IL-22 during the progression of AS. In addition, Th22 cell numbers and IL-22 levels substantially increased in mice with AS.
These results indicated that Th22 cells have a role in the development of AS. Then, we used a randomized, controlled study of animal models to investigate the role of IL-22 in AS development. We healthy controls (0.84 ± 0.18%). 37 In contrast, the results of dilated cardiomyopathy (DCM) studies showed that Th22 cells may inhibit myocardial fibrosis, indicating that these cells may have a protective role in DCM. 38 Thus, the role of Th22 cells in cardiovascular disease (CVD) needs to be further explored.
Notably, some processes previously defined as part of the 39 Another study demonstrated that although both IL-22 and IL-17 can induce the production of CXC chemokines and granulocyte clone stimulation factor in the lungs, only IL-22 can promote lung epithelial cell proliferation and strengthen the resistance to epithelial injury. 40 
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